1052 - DNA-repair gene polymorphisms associated with favorable clinical outcome following cetuximab-based therapy for elderly and multi-morbid patients wit...

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Geriatric Oncology
Head and Neck Cancers
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Yi-Fang Chang
Authors Y. Chang1, N. Su2, Y. Leu3, J. Lee3, C. Liu4, Y. Chen5, H. Chen5, I. Fang6, A. Lo6, R. Hsieh2
  • 1Hemotology And Oncology, Mackay Memorial Hospital, 104 - Taipei/TW
  • 2Hematology And Oncology, Mackay Memorial Hospital, 104 - Taipei/TW
  • 3Otolaryngology- Head &neck Surgery, Mackay Memorial Hospital, Taipei/TW
  • 4Oral And Maxillofacial Surgery, Mackay Memorial Hospital, Taipei/TW
  • 5Radiology Oncology, Mackay Memorial Hospital, Taipei/TW
  • 6Good Clinical Research Center, Mackay Memorial Hospital, Taipei/TW



Recent evidences suggest adding cetuximab to standard treatment is an effective option for recurrent and metastatic head and neck cancers. While platinum-based chemotherapy is challenging for elderly and multi-morbid patients, DNA-repair gene polymorphisms may help identifying patients who are more likely to benefit from the regimen.


Fifty-two patients were retrospectively identified from patients with treatment-naïve, primary, recurrent, or metastatic squamous cell carcinoma of the head and neck, who had received cetuximab-based therapy during 2006 and 2011. Treatment response, survival, and the presence of the single nucleotide polymorphisms, XPD-Asp312Asn, XPD-Lys751Gln, ERCC1-C8092A, and XRCC1-Arg399Gln, were currently obtained for twelve patients.


Complete or partial remission was observed in all six patients (100%) who had one or more polymorphic variants, compared to that in three of the six patients (50%) who had only common alleles (one tailed Fisher's exact test P = 0.091). Annual overall survival (OS) was 75.0% (median not reached), one-year progression-free survival (PFS) was 60.0% (median not reached) in the patients with any polymorphic variant, while one-year OS and PFS was 33.3% (median 11.5 months) and 16.7% (median 3.7 months) in the patients with only common alleles (Log-rank P = 0.321 for OS and 0.078 for PFS).


Our preliminary results suggest cetuximab might be an effective and safe option for elderly and patients with multiple comorbidities, especially for patients with DNA-repair gene polymorphic variant. Further investigation is needed to validate our findings and adjust for other prognostic factors.


All authors have declared no conflicts of interest.